Cynthia Smith
CIK: 0001609480
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 23, 2026SPRO
Spero Therapeutics, Inc.
Award(A)Direct10K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.9K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.8K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15K shares- - Jun 17, 2026AKBA
Akebia Therapeutics, Inc.
Award(A)Direct35.7K shares- - Jun 15, 2026TARA
Protara Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
31K shares- - Jun 9, 2026TVRD
Tvardi Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
6K shares- - Aug 11, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.3K shares- - Jun 20, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.1K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.8K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15.8K shares- - Jun 12, 2025SPRO
Spero Therapeutics, Inc.
Award(A)Direct20K shares- - Jun 12, 2025TARA
Protara Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
24K shares- - Jun 10, 2025AKBA
Akebia Therapeutics, Inc.
Award(A)Direct35.7K shares- - Apr 17, 2025TVRD
Tvardi Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
12K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 23, 2026 |  SPRO Spero Therapeutics, Inc. | Award(A) | 10,000 | - | $0 | Direct |
| Jun 18, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,927 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,816 | - | $0 | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 14,950 | - | - | Direct |
| Jun 17, 2026 |  AKBA Akebia Therapeutics, Inc. | Award(A) | 35,700 | - | $0 | Direct |
| Jun 15, 2026 |  TARA Protara Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 31,000 | - | - | Direct |
| Jun 9, 2026 |  TVRD Tvardi Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 6,000 | - | - | Direct |
| Aug 11, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,302 | - | - | Direct |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,120 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,816 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 15,768 | - | - | Direct |
| Jun 12, 2025 | SPRO Spero Therapeutics, Inc. | Award(A) | 20,000 | - | - | Direct |
| Jun 12, 2025 | TARA Protara Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 24,000 | - | - | Direct |
| Jun 10, 2025 | AKBA Akebia Therapeutics, Inc. | Award(A) | 35,700 | - | - | Direct |
| Apr 17, 2025 | TVRD Tvardi Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 12,000 | - | - | Direct |
1-15 of 15 transactions
About Smith Cynthia
Smith Cynthia (SEC CIK 0001609480) files insider reports with the SEC as Director of Spero Therapeutics, Inc. (SPRO), Director of AGIOS PHARMACEUTICALS, INC. (AGIO) and Director of Akebia Therapeutics, Inc. (AKBA). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 12 ownership filings by Smith Cynthia (1 Form 3, 11 Form 4), filed between Apr 17, 2025 and Jun 25, 2026. Those filings report 15 transactions, from Apr 17, 2025 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Smith Cynthia's filings is in SUGAR LAND, TX.
Recent filings by Smith Cynthia
- Jun 23, 2026: Grant or award of SPRO shares (Form 4, code A).
- Jun 18, 2026: Grant or award of AGIO derivative securities (Form 4, code A).
- Jun 18, 2026: Option exercise of AGIO shares (Form 4, code M).
- Jun 18, 2026: Grant or award of AGIO derivative securities (Form 4, code A).
- Jun 17, 2026: Grant or award of AKBA shares (Form 4, code A).
Other insiders filing for Spero Therapeutics, Inc. (SPRO)
- Zack Debra, Chief Medical Officer
- Deshpande Milind, Director
- Tregoning Kathleen, Director
- VINK PATRICK V.J.J., Director
- THOMAS FRANK E, Director
- Jackson Scott Thomas, Director